Palivizumab and the importance of cost effectiveness

BMJ (Online)

Volumn 338, Issue 7709, 2009, Pages 1474-1476

  Teale, Alison ^a   Deshpande, Sanjeev ^b   Burls, Amanda ^c  

^a West Midlands Specialised Commissioning Team   (United Kingdom)

^b ROYAL SHREWSBURY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MOTAVIZUMAB; PALIVIZUMAB;

BRONCHIOLITIS; CHRONIC LUNG DISEASE; CONGENITAL HEART DISEASE; COST EFFECTIVENESS ANALYSIS; DEATH; DRUG EFFICACY; FUNDING; HEALTH CARE POLICY; HEALTH SERVICE; HOSPITAL ADMISSION; HUMAN; IMMUNE DEFICIENCY; INFECTION PREVENTION; INTENSIVE CARE UNIT; MEDICAL DECISION MAKING; NATIONAL HEALTH SERVICE; PATIENT; PHYSICIAN; PREMATURITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SHORT SURVEY;

EID: 67650072486     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (5)

1. Department of Health. World Class Commissioning: Vision. London: Stationery Office, 2007.
2. Department of Health. Joint Committee on Vaccination and Immunisation: minutes of the meeting held on Friday 1 November 2002. www.advisorybodies. doh.gov.uk/JCVI/mins01nov02.htm.
3. Department of Health. Joint Committee on Vaccination and Immunisation: minutes of the meeting held on Wednesday 22 June 2005. www.advisorybodies. doh.gov.uk/jcvi/mins220605.htm.
4. London New Drugs Group. 4. APC/DTC Briefing: Palivizumab for the prevention of respiratory syncytial virus (RSV). September 2006. http://www.nelm.nhs.uk/en/Download/?file= MDs0OTcwNzk7RXZpZGVuY2UvRHJ1ZyBTcGVjaWZpYyBSZXZpZXdzL3BhbGl2aXp1bWFiIDIzL TExLTA2LnBkZg.
5. Wang D, Cummins C, Bayliss J, Sandercock J, Burls A. Immunoprophylaxis against RSV with palivizumab in children - a systematic review and economic evaluation. Health Technol Assess 2008;12(36). www.ncchta.org/fullmono/ mon1236.pdf.